NewsBenzingaKodiak Sciences Says Phase 3 DAYBREAK Study Met Primary Endpoints With Zenkuda (Tarcocimab Tedromer) And Tabirafusp-ted (KSI-501) Showing Non-inferiority In Vision Gains For Wet Age-related Macular Degeneration Vs. Aflibercept At Year One Kodiak Sciences Says Phase 3 DAYBREAK Study Met Primary Endpoints With Zenkuda (Tarcocimab Tedromer) And Tabirafusp-ted (KSI-501) Showing Non-inferiority In Vision Gains For Wet Age-related Macular Degeneration Vs. Aflibercept At Year One Benzinga 2026.09.28 10:34 (GMT+0) Open on Benzinga Other news RTX Corporation: Improving Margins Could Unlock More Value From Its Backlog (NYSE:RTX) Nvidia Adds $150 Billion to Share Buyback Authorization, Bringing Total to $235 Billion Options Action: Naked Put Trade Ideas for this Week Citi Raises Estimates for Micron Ahead of Earnings. How to Play MU Stock Now. As Cadence Strengthens Its Partnership With TSMC, Here's What It Could Mean for AI Stocks UBS Started Coverage of CoreWeave With a ‘Buy’ Rating. What This Means for CRWV Stock.
